Results 51 to 60 of about 154,948 (311)

Engineered Brain‐Targeted Exosomes Delivering FGF1 for Sustained Glycemic Regulation and Multitarget Neurovascular Protection in Diabetic Stroke

open access: yesAdvanced Science, EarlyView.
ABSTRACT Diabetic stroke is characterized by a hyperglycemic and pro‐inflammatory microenvironment that exacerbates neurovascular dysfunction. However, the blood–brain barrier (BBB) remains a formidable obstacle, restricting the delivery of most therapeutic molecules.
Bixin Shen   +7 more
wiley   +1 more source

TNF-α (−308) Gene Polymorphism and Type 2 Diabetes Mellitus in Ethiopian Diabetes Patients

open access: yesDiabetes, Metabolic Syndrome and Obesity, 2019
Birhanu Ayelign,1 Meaza Genetu,1 Tadelo Wondmagegn,1 Gashaw Adane,1 Markos Negash,1 Nega Berhane2 1Department of Immunology and Molecular Biology, School of Biomedical and Laboratory Science, College of Medicine and Health Science, University of Gondar ...
Ayelign B   +5 more
doaj  

Effect of carbohydrate intake on glycemic control among adult patients with type 2 diabetes mellitus attending Diabetes and Endocrine Diseases Center in Babel, 2022

open access: yesMedical Journal of Babylon, 2023
Background: Diabetes mellitus is a well-known chronic, metabolic disease characterized by elevated levels of blood glucose (BG) due to obsolete or relative insulin deficiency among other pathophysiological defects.
Ali Mousa Essa Albadri, Jawad K Al-Diwan
doaj   +1 more source

OAF Blocks SIAH1‐Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD

open access: yesAdvanced Science, EarlyView.
This study shows OAF directly binds to SCPX and inhibits its interaction with the E3 ligase SIAH1, thereby protecting SCPX from ubiquitin‐dependent degradation and stabilizing its levels. This OAF‐SCPX axis represents a novel pathway in lipid homeostasis, highlighting OAF as a promising therapeutic candidate for MASLD.
Zongxi Li   +11 more
wiley   +1 more source

Chinese Expert Consensus on the Clinical Application of Finerenone in Geriatric Comorbidities

open access: yesAGING MEDICINE, EarlyView.
Mineralocorticoid receptor (MR) overactivation drives inflammation, oxidative stress, and fibrosis in the heart, kidneys, and vasculature, leading to cardiorenal dysfunction. MR signaling promotes hypertrophy, remodeling, and injury through pathways like oxidative stress and inflammation, resulting in vascular stiffness and progressive organ damage ...
Xiaoming Wang, Cuntai Zhang
wiley   +1 more source

Polycystic Ovary Syndrome (PCOS): Insights into Etiology, Genetic, Diagnosis, Treatment, and Future Directions. (A Comprehensive Review) [PDF]

open access: yesمجلة التربية والعلم
In this paper, we obtained the nuclear energy levels for 48Cr isotope that resided in the pf -shell of shell model calculations. For nucleons that were outside closed and no core, they were calculated using skyrme interactions. The Skyrme (SLY5) was used
Lujain Ghannawi   +4 more
doaj   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

T2DM and anxiety

open access: yes, 2021
Study conducted in the region of Tumbes, in the north of Peru to assess the diagnostic accuracy of different risk scores and T2DM.
Antonio Bernabe-Ortiz (4099528)
core   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić   +7 more
wiley   +1 more source

T2DM 的 GWAS 数据

open access: yes, 2023
T2DM 的 GWAS ...
nanyu liu (16857975)
core   +1 more source

Home - About - Disclaimer - Privacy